Non-cirrhotic portal hypertension associated with multicentric Castleman’s disease: a case report

ease. Osteoporos Int. 2013;24:2929–2953. [3] Maillefert J, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219–1222. [4] Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood. 2011;117:4701–4705. [5] Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308. [6] Birtle AJ, Freeman A, Masters JR, et al. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the “PSA negative” patients. Cancer. 2003;98:2362–2367. [7] Alexandru D, So W. Evaluation and management of vertebral compression fractures. Perm J. 2012;16:46–51. [8] O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202–211. [9] Graus F, Ari~ no H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123:3230–3238. [10] Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v125. [11] Conlan MG, Bast M, Armitage JO, et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska lymphoma study group. J Clin Oncol. 1990;8: 1163–1172. [12] Wu H, Bui MM, Leston DG, et al. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas. BMC Cancer. 2014;14:900.

[1]  Dermot Kelleher,et al.  Idiopathic multicentric Castleman's disease: a systematic literature review. , 2016, The Lancet. Haematology.

[2]  J. Rossi,et al.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Oncology.

[3]  F. van Rhee,et al.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. , 2014, Blood.

[4]  D. Weisenburger,et al.  The clinical spectrum of Castleman's disease , 2012, American journal of hematology.

[5]  K. Gutkowski,et al.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. , 2011, World journal of gastroenterology.

[6]  A. Hokama,et al.  Nodular Regenerative Hyperplasia of the Liver and Castleman’s Disease: Potential Role of Interleukin-6 , 2005, Digestive Diseases and Sciences.

[7]  R. Andrade,et al.  CASE REPORT: Portal Hypertension and Refractory Ascites Associated with Multicentric Castleman's Disease , 2000, Digestive Diseases and Sciences.

[8]  P. Musiani,et al.  Coexpression of IL‐6 and soluble IL‐6R causes nodular regenerative hyperplasia and adenomas of the liver , 1998, The EMBO journal.

[9]  J. Herrada,et al.  The Clinical Behavior of Localized and Multicentric Castleman Disease , 1998, Annals of Internal Medicine.

[10]  T. Molina,et al.  Hepatic lesions of vascular origin in multicentric Castleman's disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia. , 1995, Pathology, research and practice.

[11]  R. Andrade,et al.  Portal hypertension and refractory ascites associated with multicentric Castleman's disease. , 2000, Digestive Diseases and Sciences.

[12]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.